When compared among different brain cancer types, both FREM2 and SPRY1 showed significantly higher expression in GBM versus LGG (3-fold, 10-fold, respectively), as shown in Figure 5B. FREM2 and SPRY1 expression in the reference nonmalignant brain tissue samples (norm). This evidence concerns the gene SPRY1 and glioblastoma.